Astel­las and Seagen's Pad­cev wins full FDA ap­proval, notch­ing ex­pand­ed la­bel in tough-to-crack urothe­lial can­cer

Two years af­ter Seagen and Astel­las won a con­di­tion­al FDA ap­proval to tar­get urothe­lial can­cer, the pair’s Pad­cev drug has been giv­en a full en­dorse­ment from reg­u­la­tors.

The FDA grant­ed full ap­proval and a la­bel ex­pan­sion for Pad­cev to treat pa­tients with ad­vanced or metasta­t­ic urothe­lial can­cer who aren’t el­i­gi­ble for cis­platin chemo, the com­pa­ny an­nounced on Fri­day. Pad­cev is now avail­able for sec­ond-line pa­tients, and the OK is the first for those who have pre­vi­ous­ly re­ceived im­munother­a­py and can­not re­ceive cis­platin, the com­pa­nies said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER